Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis

被引:7
|
作者
Kooloos, Wouter M. [1 ]
Wessels, Judith A. M. [1 ]
van der Straaten, Tahar [1 ]
Allaart, Cornelia F.
Huizinga, Tom W. J.
Guchelaar, Henk-Jan [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, NL-2300 RC Leiden, Netherlands
关键词
functionality; methotrexate; pharmacogenetics; replication study; rheumatoid arthritis; SNP; TOLL-LIKE RECEPTORS; SINGLE-NUCLEOTIDE POLYMORPHISMS; DIHYDROFOLATE-REDUCTASE GENE; MULTIDRUG-RESISTANCE GENE; BLOOD MONONUCLEAR-CELLS; HLA-G GENOTYPE; P-GLYCOPROTEIN; TRANSFORMING-GROWTH-FACTOR-BETA-1; GENE; ENHANCED EXPRESSION; CONTROLLED-TRIAL;
D O I
10.2217/PGS.09.139
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims: Clinical response to methotrexate (MTX) treatment differs among rheumatoid arthritis patients. Genetic variation can partly account for this phenomenon. In this study, functional polymorphisms in genes related to the mechanism of action of MTX or immunopathogenesis of rheumatoid arthritis were studied for association with treatment outcome in a Dutch cohort of patients with early rheumatoid arthritis. Furthermore, tests for replication of previous research on these genetic variants were performed according to reported end points. Materials & methods: Seven polymorphisms in seven genes were analyzed in 205 genotyped patients with active rheumatoid arthritis. All patients received standardized MTX treatment (<= 25 mg per week orally) combined with folic acid. MTX treatment outcome was evaluated by disease activity score criteria and adverse drug events. The following genetic variants were analyzed and correlated: ABCB1 3435C > T, ITPA IVS2 +21A > C, HLA-G (-14 bp >+14 bp), TGFB1 +869T > C and TLR4 +896A > G. In case of significant differences, regression analyses were applied. Since carriers of the minor alleles of the SNPs DHFR 829C > T and IMPDH2 +787C > T were not observed, no statistical analyses could be performed. Results: No significant associations or replications of these genetic variants with MTX efficacy were demonstrated. Regarding toxicity, patients carrying the ABCB1 3435T-allele and TLR4 +896G-allele were 2.5-times more likely to develop adverse drug events at 6 months (odds ratio: 2.6; 95% CI: 1.1-6.2, and odds ratio: 2.5; 95% CI: 1.1-6.1, respectively). Additionally, this chance increased almost fourfold in patients with the two unfavorable genotypes (odds ratio: 3.9; 95% CI: 1.5-10.3). However, none of these associations remained significant after correction for multiple testing (p < 0.004). Conclusion: Our data indicate that MTX toxicity was potentially associated with ABCB1 3435C > T and TLR4 +896A > G. However, after correction, none of these associations remained significant. Furthermore, no significant associations or replications of these functional variants with efficacy were found.
引用
收藏
页码:163 / 175
页数:13
相关论文
共 50 条
  • [1] Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis
    Wessels, Judith A. M.
    Kooloos, Wouter M.
    de Jonge, Robert
    de Vries-Bouwstra, Jeska K.
    Allaart, Cornelia F.
    Linssen, Annelies
    Collee, Gerard
    de Sonnaville, Peter
    Lindemans, Jan
    Huizinga, Tom W. J.
    Guchelaar, Henk-Jan
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : 2830 - 2839
  • [2] Genetic variants in adenosine pathway for methotrexate treatment outcome in recent onset rheumatoid arthritis
    Wessels, J. A. M.
    Kooloos, W. M.
    De Jonge, R.
    De Vries-Bouwstra, J. K.
    Allaart, C. F.
    Linssens, A.
    Collee, G.
    De Sonnaville, P.
    Lindemans, J.
    Huizinga, T. W. J.
    Guchelaar, H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 349 - 349
  • [3] A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis
    Wessels, Judith A. M.
    van der Kooij, Sjoerd M.
    le Cessie, Saskia
    Kievit, Wietske
    Barerra, Pilar
    Allaart, Cornelia F.
    Huizinga, Tom W. J.
    Guchelaar, Henk-Jan
    [J]. ARTHRITIS AND RHEUMATISM, 2007, 56 (06): : 1765 - 1775
  • [4] Treatment of recent-onset rheumatoid arthritis: Lessons from the BeSt study
    Allaart, Cornelia F.
    Breedveld, Ferdinand C.
    Dijkmans, Ben A. C.
    [J]. JOURNAL OF RHEUMATOLOGY, 2007, 34 : 25 - 33
  • [5] Weekly leflunomide as monotherapy for recent-onset rheumatoid arthritis
    Jakez-Ocampo, J
    Richaud-Patin, Y
    Granados, J
    Sánchez-Guerrero, J
    Llorente, L
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2004, 51 (01): : 147 - 148
  • [6] Potential role of calprotectin as a monitoring biomarker for clinical and sonographic activity and treatment outcome in recent-onset rheumatoid arthritis
    Amal F. Soliman
    Basant M. Elnady
    Raneyah H. Mahmoud Shaker
    Amira I. Mansour
    [J]. Egyptian Rheumatology and Rehabilitation, 2016, 43 (3) : 143 - 149
  • [7] Short-term outcomes in recent-onset rheumatoid arthritis
    Young, A
    [J]. BRITISH JOURNAL OF RHEUMATOLOGY, 1995, 34 : 79 - 86
  • [8] ANTIBODIES TO SYNOVIAL ANTIGENS IN RECENT-ONSET RHEUMATOID-ARTHRITIS
    MCCOLL, GJ
    CRAM, DS
    HARRISON, LC
    [J]. ARTHRITIS AND RHEUMATISM, 1995, 38 (09): : 384 - 384
  • [9] ANTIBODIES TO SYNOVIAL ANTIGENS IN RECENT-ONSET RHEUMATOID-ARTHRITIS
    MCCOLL, GJ
    CRAM, DS
    HARRISON, LC
    [J]. ARTHRITIS AND RHEUMATISM, 1995, 38 (10): : 1418 - 1428
  • [10] Interleukin-6 receptor in the recent-onset rheumatoid arthritis
    Marco Antonio Montes-Cano
    Sonsoles Reneses
    Jose Raul García-Lozano
    Fuensanta Torrecillas
    Cristina Abad-Molina
    Alicia García
    Antonio Núñez Roldán
    Maria Francisca González-Escribano
    [J]. Journal of Translational Medicine, 9 (Suppl 2)